Improving results with assisted reproductive technologies: Individualized patient-tailored strategies for ovulation induction

Reproductive BioMedicine Online

Volumn 9, Issue 1, 2004, Pages 43-46

  Penzias, Alan S ^a  

^a BOSTON IVF   (United States)

Author keywords

Assisted reproduction; Individualized treatment; Infertility treatment; Outcome; Patient experience

Indexed keywords

GONADORELIN AGONIST; GONADORELIN ANTAGONIST; PROGESTERONE; RECOMBINANT FOLLITROPIN;

ARTICLE; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; OUTCOMES RESEARCH; OVULATION INDUCTION; PATIENT MONITORING; PRACTICE GUIDELINE; RELIABILITY; REPRODUCTIVE SUCCESS; STANDARDIZATION; TREATMENT PLANNING;

EID: 3242702329     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)62108-6     Document Type: Article

References (14)

1. Driebergen R, Baer G 2003 Quantification of follicle stimulating hormone (follitropin alfa): is in vivo bioassay still relevant in the recombinant age? Current Medical Research and Opinion 19, 41-46.
2. Duijkers JJ, Klipping C, Mulders TM et al. 1997 Pharmacodynamics and pharmacokinetics after repeated subcutaneous administration of three gonadotrophin preparations. Human Reproduction 12, 2379-2384.
3. Engel JB, Olivennes F, Fanchin R et al. 2003 Single dose application of cetrorelix in combination with clomiphene for friendly IVF: results of a feasibility study. Reproductive BioMedicine Online 6, 444-447.
4. Felberbaum R, Diedrich K 2003 Gonadotrophin-releasing hormone antagonists: will they replace the agonists? Reproductive BioMedicine Online 6, 43-53.
5. Gleicher N, Vanderlaan B, Karande V et al. 1996 Infertility treatment dropout and insurance coverage. Obstetrics and Gynecology 88, 289-293.
6. Hoomans EHM, Nyboe Andersen A, Loft A et al. 1999 A prospective, randomized clinical trial comparing 150 IU of recombinant follicle stimulating hormone and 225 IU highly purified urinary follicle stimulating hormone in a fixed dose regimen in women undergoing ovarian stimulation. Human Reproduction 14, 2442-2447.
7. Hugues JN, Barlow DH, Rosenwaks Z et al. 2003 Improvement in consistency of response to ovarian stimulation with recombinant human follicle stimulating hormone resulting from a new method for calibrating the therapeutic preparation. Reproductive BioMedicine Online 6, 185-190.
8. Penzias AS 2002 Luteal phase support. Fertility and Sterility 77, 318-323.
9. Penzias AS 2004 When and why does the dream die? or does it? Fertility and Sterility 81, 274-275.
10. Popovic-Todorovic B, Loft A, Lindhard A et al. 2003 A prospective study of predictive factors of ovarian response in 'standard' IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant dosage normogram. Human Reproduction 18, 781-787.
11. Rector NA, Markusen TE, Stone BA et al. 1993 Numbers and quality of oocytes after induction of multiple folliculogenesis in women and in mice with different lots of human menopausal gonadotropins. Fertility and Sterility 60, 1082-1087.
12. Redmond ML, Harrison RF 2000 Evaluating practice at an Irish tertiary level fertility clinic 1995/98. Irish Medical Journal 93, 112-114.
13. Rísquez F 2001 Induction of follicular growth and ovulation with urinary and recombinant gonadotrophins. Reproductive BioMedicine Online 3, 54-72.
14. United States Pharmacopeial Convention Inc. 2004 The Pharmacopeia of the United States Twenty-seventh Revision (USP 27). The United States Pharmacopeial Convention Inc. Rockville, MD, pp. 1157-1159.